Analysis of differentially expressed genes in neuroendocrine carcinomas of the lung

Journal of Thoracic Oncology

Volumn 1, Issue 8, 2006, Pages 780-786

  Okubo, Chigusa ^a   Minami, Yuko ^a,c   Tanaka, Ryota ^a,d   Uchihara, Teruhito ^a,e   Anami, Yoichi ^a   Furuya, Shuichiroh ^b   Morishita, Yukio ^a   Iijima, Tatsuo ^a   Noguchi, Masayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d GUNMA PREFECTURAL CANCER CENTER   (Japan)

^e UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Lung; Neuroendocrine carcinoma; Neuronatin; Suppression subtractive hybridization; TALPAT

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; NEURONATIN; PROTEIN; UNCLASSIFIED DRUG; CD56 ANTIGEN; CHROMOGRANIN A; MEMBRANE PROTEIN; NERVE PROTEIN; NNAT PROTEIN, HUMAN; SYNAPTOPHYSIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DISEASE MARKER; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG CARCINOMA; MALE; MARKER GENE; MITOCHONDRIAL GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SMALL CELL CARCINOMA; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; TISSUE SECTION; ANIMAL; CARCINOMA; DIFFERENTIAL DIAGNOSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; MOUSE MUTANT;

ANIMALS; ANTIGENS, CD56; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; CHROMOGRANIN A; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, SCID; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; SYNAPTOPHYSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 34248384479     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200610000-00005     Document Type: Article

References (56)

1. Travis WD, Colby TV, Corrin B, et al. World Health Organization. International Histological Classification of Tumors. Histological Typing of Lung and Pleural Tumors, 3rd ed. Berlin: Springer, 1999.
2. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-944.
3. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006;24:70-76.
4. Ullmann R, Schwendel A, Klemen H, et al. Unbalanced chromosomal aberrations in neuroendocrine lung tumors as detected by comparative genomic hybridization. Hum Pathol 1998;29:1145-1149.
5. Ullmann R, Petzmann S, Sharma A, et al. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol 2001;32:1059-1063.
6. Shin JH, Kang SM, Kim YS, et al. Identification of tumor suppressor loci on the long arm of chromosome 5 in pulmonary large cell neuroendocrine carcinoma. Chest 2006;128:2999-3003.
7. Kobayashi Y, Tokuchi Y, Hashimoto T, et al. Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors. Cancer Sci 2004;95:334-341.
8. Jones MH, Yamakawa K, Nakamura Y. Isolation and characterization of 19 dinucleotide repeat polymorphisms on chromosome 3p. Hum Mol Genet 1992;1:131-133.
9. Tokuchi Y, Kobayashi Y, Hayashi S, et al. Abnormal FHIT transcripts found in both lung cancer and normal lung tissue. Genes Chromosomes Cancer 1999;24:105-111.
10. Wieland I, Bohm M, Arden KC, et al. Allelic deletion mapping on chromosome 5 in human carcinomas. Oncogene 1996;12:97-102.
11. Gyapay G, Morissette J, Vignal A, et al. The 1993-94 Genethon human genetic linkage map. Nat Genet 1994;7:246-339.
12. Kwiatkowski DJ, Henske EP, Weimer K, et al. Construction of a GT polymorphism map of human 9q. Genomics 1992;12:229-240.
13. Manickam P, Guru SC, Debelenko LV, et al. Eighteen new polymorphic markers in the multiple endocrine neoplasia type 1 (MEN1) region. Hum Genet 1997;101:102-108.
14. Toguchida J, McGee TL, Paterson JC, et al. Complete genomic sequence of the human retinoblastoma susceptibility gene. Genomics 1993;17:535-543.
15. Jones MH, Nakamura Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer 1992;5:89-90.
16. Hiroshima K, Iyoda A, Shibuya K, et al. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer 2004;100:1190-1198.
17. Zaffaroni N, De Polo D, Villa R, et al. Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping. J Pathol 2003;201:127-133.
18. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795.
19. Virtanen C, Ishikawa Y, Honjoh D, et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci USA 2002;99:12357-12362.
20. Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004;363:775-781.
21. Sturm N, Lantuejoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001;32:918-925.
22. Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002;33:175-182.
23. Araki K, Ishii G, Yokose T, et al. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2003;40:173-180.
24. Pelosi G, Pasini F, Fraggetta F, et al. Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 2003;42:203-213.
25. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-1952.
26. Jiang SX, Kameya T, Shinada J, et al. The significance of frequent and independent p53 and bcl-2 expression in large-cell neuroendocrine carcinomas of the lung. Mod Pathol 1999;12:362-369.
27. Gouyer V, Gazzeri S, Bolon I, et al. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 1998;18:188-196.
28. Gurskaya NG, Diatchenko L, Chenchik A, et al. Equalizing cDNA subtraction based on selective suppression of polymerase chain reaction: cloning of Jurkat cell transcripts induced by phytohemaglutinin and phorbol 12-myristate 13-acetate. Anal Biochem 1996;240:90-97.
29. Diatchenko L, Lau YF, Campbell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 1996;93:6025-6030.
30. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529-553.
31. Aoyagi K, Tatsuta T, Nishigaki M, et al. A faithful method for PCR-mediated global mRNA amplification and its integration into microarray analysis on laser-captured cells. Biochem Biophys Res Commun 2003;300:915-920.
32. Yokota N, Mainprize TG, Taylor MD, et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 2004;23:3444-3453.
33. Chen X, Halberg RB, Ehrhardt WM, et al. Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci USA 2003;100:9530-9535.
34. Lee KF, Kwok KL, Chung MK, et al. Phospholipid transfer protein (PLTP) mRNA expression is stimulated by developing embryos in the oviduct. J Cell Biochem 2006;95:740-749.
35. Shackel NA, McGuinness PH, Abbott CA, et al. Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. Hepatology 2003;38:577-588.
36. Brown MD, Voljavec AS, Lott MT, et al. Mitochondrial DNA complex I and III mutations associated with Leber's hereditary optic neuropathy. Genetics 1992;130:163-173.
37. Johns DR, Neufeld MJ. Cytochrome b mutations in Leber hereditary optic neuropathy. Biochem Biophys Res Commun 1991;181:1358-1364.
38. Mackey DA, Oostra RJ, Rosenberg T, et al. Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. Am J Hum Genet 1996;59:481-485.
39. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
40. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998;20:291-293.
41. Okura T, Koda M, Ando F, et al. Association of the mitochondrial DNA 15497G/A polymorphism with obesity in a middle-aged and elderly Japanese population. Hum Genet 2003;113:432-436.
42. Torigoe T, Izumi H, Ishiguchi H, et al. Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem 2002;277:36534-36543.
43. Dou D, Joseph R. Structure and organization of the human neuronatin gene. Genomics 1996;33:292-297.
44. Dou D, Joseph R. Cloning of human neuronatin gene and its localization to chromosome-20q 11.2-12: the deduced protein is a novel "proteolipid." Brain Res 1996;723:8-22.
45. Kikyo N, Williamson CM, John RM, et al. Genetic and functional analysis of neuronatin in mice with maternal or paternal duplication of distal Chr 2. Dev Biol 1997;190:66-77.
46. Wijnholds J, Chowdhury K, Wehr R, et al. Segment-specific expression of the neuronatin gene during early hindbrain development. Dev Biol 1995;171:73-84.
47. Evans HK, Wylie AA, Murphy SK, et al. The neuronatin gene resides in a "micro-imprinted" domain on human chromosome 20q11.2. Genomics 2001;77:99-104.
48. Kagitani F, Kuroiwa Y, Wakana S, et al. Peg5/neuronatin is an imprinted gene located on sub-distal chromosome 2 in the mouse. Nucleic Acids Res 1997;25:3428-3432.
49. Kiyosawa H, Yamanaka I, Osato N, et al. Antisense transcripts with FANTOM2 clone set and their implications for gene regulation. Genome Res 2003;13:1324-1334.
50. Okazaki Y, Furuno M, Kasukawa T, et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature 2002;420:563-573.
51. Kiyosawa H, Kawashima T, Silva D, et al. Systematic genome-wide approach to positional candidate cloning for identification of novel human disease genes. Intern Med J 2004;34:79-90.
52. Kuerbitz SJ, Pahys J, Wilson A, et al. Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia. Carcinogenesis 2002;23:559-564.
53. John RM, Aparicio SA, Ainscough JF, et al. Imprinted expression of neuronatin from modified BAC transgenes reveals regulation by distinct and distant enhancers. Dev Biol 2001;236:387-399.
54. Hu Y, Ippolito JE, Garabedian EM, et al. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002;277:44462-44474.
55. Usui H, Morii K, Tanaka R, et al. cDNA cloning and mRNA expression analysis of the human neuronatin. High level expression in human pituitary gland and pituitary adenomas. J Mol Neurosci 1997;9:55-60.
56. Becker M, Sommer A, Kratzschmar JR, et al. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 2006;4:151-168.